CD19 and acute lymphoblastic leukemia: Chimeric antigen receptor (CAR) T-cells have largely replaced DLI for treating CD19+ leukemic relapse (e.g. B-ALL) after alloHCT, with high complete remission rates and durable responses reported in relapsed/refractory settings (53–57).